Cryoport Inc. held a ribbon-cutting ceremony to celebrate the opening of its new Global Logistics Center in Livingston, it announced Tuesday.
Cryoport is a temperature controlled logistics company that focuses on the life sciences industry. It is based in Irvine, California.
The company’s CEO, Jerrill Shelton, said his company chose Livingston due to it being a major biotechnology hub.
“Launching our new Global Logistics Center in Livingston enables us to provide even faster service and, in some cases, same-day delivery to support our clients’ manufacturing operations, not just in the U.S. but worldwide, effectively, efficiently and safely. Our Global Logistics Centers are designed to be inherently scalable and supportive of life sciences industry needs. We expect commercial regenerative therapies to continue to ramp over time. Livingston, New Jersey is a major biotech hub with robust, large, well-established biopharmaceutical companies along with innovative startups, incubator sites and large biotech-focused research institutions, many of whom are already partnered with Cryoport for their temperature-controlled logistics requirements. This makes it an ideal location,”  Shelton said.
The ceremony was attended by Cryoport clients, local dignitaries and business partners.
The new logistics center will help the company more effectively support its biopharmaceutical clients, it said. It will help meet the needs of the regenerative therapy market as clinical trials increase in the industry as well as ramping of commercial products it currently supports by investing in its infrastructure. The entire center will offer temperature-controlled solutions.
“Many of our biopharma clients are predicting significant increases in the number of regenerative therapy clinical trials they expect to undertake. This is, in fact, a time when the industry is reaching an inflection point with a number of FDA-approved therapies now approaching the launching stage in the commercial market. Reliable and efficient management of the biopharma supply chain is critical to advancing the plans of these clients, who are developing and bringing to market the next generation of regenerative therapies, which will surely impact the practice of medicine in profound ways. To support this, reliable and efficient management of the biopharma supply chain is critical. At Cryoport, we are constantly focused on improving our competencies and providing best-in-class service to meet these needs,” Shelton said.
Novartis, Celgene and bluebird bio are among Cryoport’s clients that will be supported from Livingston.
